AirNet Technology raises $180 million in digital assets offering
In a recent filing with the Securities and Exchange Commission, Prasad Raju, the Chief Financial Officer of CRISPR Therapeutics AG (NASDAQ:CRSP), disclosed the sale of 3,762 common shares. The transaction, which took place on March 17, 2025, was executed at a price of $41.80 per share, amounting to a total of $157,251. The sale price was slightly above the current market price of $40.97, with the stock showing a year-to-date gain of 8.79% despite a challenging -40.09% return over the past year. According to InvestingPro analysis, CRSP currently appears slightly undervalued.
This sale was conducted to cover the tax withholding obligations related to the vesting of restricted stock units, as mandated by the company’s RSU Settlement Policy. Following the sale, Raju retains ownership of 12,714 shares in the company. InvestingPro data reveals that CRSP’s stock movements are quite volatile, which is one of several key insights available in the comprehensive Pro Research Report covering this $3.52 billion market cap company.
In addition to the sale, the filing also reported several acquisitions of securities. Raju acquired 10,000 common shares through the vesting of restricted stock units on March 14, 2025. Moreover, he was granted stock options for 36,666 shares and 27,500 restricted stock units, both with no immediate cash outlay.
These transactions reflect the ongoing management of equity compensation by CRISPR Therapeutics’ CFO, ensuring compliance with company policies and tax obligations.
In other recent news, CRISPR Therapeutics has been the focus of several analyst updates and developments. Citi analysts reduced the price target for CRISPR Therapeutics to $82 while maintaining a Buy rating, highlighting the progress of Casgevy with over 50 treatment centers activated globally. Evercore ISI upgraded CRISPR Therapeutics from In Line to Outperform, raising the price target to $99, driven by optimism about upcoming catalysts such as the in vivo programs CTX320 and CTX310. Stifel, however, took a more cautious approach, lowering the price target to $49 but maintaining a Hold rating, citing concerns about the market uptake of Casgevy.
Meanwhile, TD Cowen upgraded CRISPR Therapeutics from Sell to Hold, keeping the price target at $35, and noted a reduced downside risk for the company’s shares. The firm’s analysts have expressed caution regarding the launch of Casgevy but acknowledged the potential for positive developments in the pipeline. CRISPR Therapeutics reported growth in Casgevy cell collections, with over 50 new collections in the final nine weeks of the fourth quarter. The company continues to guide for strong growth in cell collections throughout 2025, supported by a cash reserve of $1.9 billion. Investors are closely watching CRISPR Therapeutics as the company navigates these developments and anticipates significant updates in 2025.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.